The strong Q2 results and reiterated FY2026 guidance confirm the growth trajectory. The new 5% buyback authorization signals management's confidence and capital allocation discipline. Monitor Q3 and Q4 revenue cadence against the guided sequential growth pattern for confirmation.
Price Chart
Executive Summary
VieMed Healthcare filed an 8-K with an investor presentation (EX-99.1) covering record 2025 results, continued momentum in H1 2026, and FY2026 guidance. Q2 2026 revenue grew 24% YoY to $78.1M, Adjusted EBITDA was $13.7M, and the company generated $8.6M of free cash flow. The board authorized a new share repurchase program for up to 5% of shares outstanding. The filing is a routine investor update with no new material financial disclosures beyond what was previously communicated, but the strong operational trends and capital return authorization are notable positives.
Key Facts
- Q2 2026 net revenue of $78.1M, up 24% YoY
- Q2 2026 Adjusted EBITDA of $13.7M
- Q2 2026 net income attributable to VMD of $2.8M
- TTM free cash flow of $34.4M as of Q2 2026
- FY2026 guidance: net revenue $314M-$320M, Adjusted EBITDA $64M-$68M
- Board authorized a new share repurchase program for up to 5% of shares outstanding
- 1H 2026: 680,802 shares repurchased at avg price of $9.57/share
- Vent patients reached all-time high of 12,635 in Q2 2026, up 4% YoY
- Sleep therapy patients up 44% YoY in Q2 2026
- Zero net debt and $46M credit facility availability as of June 30, 2026
Financial Impact
Q2 2026 revenue $78.1M (+24% YoY), Adjusted EBITDA $13.7M, net income $2.8M, TTM FCF $34.4M. FY2026 guidance midpoint: revenue $317M, Adjusted EBITDA $66M.
Risk Factors
- Gross margin compression from service mix shift (57.5% in FY2025 vs 61.6% in FY2023)
- Near-term operational friction from new NCD ventilation coverage standards
- Dependence on few payors and potential reimbursement rate reductions
- Integration risk from M&A pipeline execution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001729149-26-000048 |
| Document: vmd-20260820.htm | 0001729149-26-000048 |
| Document: 0001729149-26-000048-index-headers.html | 0001729149-26-000048 |
| Document: 0001729149-26-000048-index.html | 0001729149-26-000048 |
| Document: 0001729149-26-000048.txt | 0001729149-26-000048 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 24, 2026 4w ago | SC 13D/A | $8.91 $9.11 | ▼ −2.24% | ▼ −2.99% | $9.73 (−9.20%) |
Aug 20, 2026 9w ago | 8-K | $8.85 $9.09 | ▲ +2.71% | ▲ +3.01% | $9.73 (+9.94%) |
Aug 3, 2026 12w ago | 8-K | $9.84 $9.82 | ▼ −0.15% | ▲ +0.05% | $9.73 (−1.07%) |
Jun 4, 2026 20w ago | 8-K | $9.97 $9.92 | ▼ −0.50% | ▼ −0.73% | $9.73 (−2.41%) |
Jun 2, 2026 20w ago | 8-K | $9.56 $9.84 | ▲ +2.93% | ▲ +2.53% | $9.73 (+1.78%) |
May 5, 2026 24w ago | 8-K | $8.52 $8.52 | · 0.00% | ▲ +0.33% | $9.73 (+14.27%) |
Mar 4, 2026 33w ago | 8-K | $8.40 $8.78 | ▲ +4.52% | ▲ +5.84% | $9.73 (+15.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers